Table 2.

Results of genetic testing in the study group (80 patients with pES)

Gene (no. of patients)Mutation type and consequences
Pathogenic mutations, n = 32, 40%  
 TNFRSF6 (6) Heterozygous/LOF 
 CTLA4 (8) Heterozygous/LOF 
 STAT3 (6) Heterozygous/GOF 
 PIK3CD (1) Hetezozygous/GOF 
 CBL (1) Heterozygous/LOF 
 ADAR1 (1) Heterozygous/LOF 
 LRBA (4) Homozygous/LOF 
 RAG 1 (2) Compound heterozygous/LOF 
 TNFRSF6 somatic (1) Heterozygous/LOF 
 KRAS somatic (2) Heterozygous/GOF 
Probably pathogenic mutations, n = 20, 25%  
 Immune cell receptors  
  IFNAR1 (1) Homozygous/likely LOF 
  TNFR2 (1) Heterozygous/likely GOF 
  TGFBR2 (1) Heterozygous/likely LOF 
 Intracellular signaling  
  JAK1 (2) Heterozygous/likely GOF 
  JAK2 (1) Heterozygous/likely GOF 
  PLCG2 (1) Heterozygous/likely GOF 
  TRAF3 (1) Heterozygous/likely GOF 
  CARD11 (1) Heterozygous/likely GOF 
  ARHGEF4 (1) Heterozygous/likely GOF 
  PTPN11 (1) Heterozygous/likely GOF 
  PARP4 (1) Compound heterozygous/likely LOF 
 Apoptosis regulation  
  RIPK2 (2) Heterozygous/likely LOF 
  APAF1 (1) Heterozygous/likely GOF 
 Transcription factors  
  IKZF1 (2) Heterozygous/likely GOF 
  NFATC1 (2) Heterozygous/likely GOF 
  IKZF2 (1) Heterozygous/likely LOF 
No genetic abnormalities, n = 28, 35%  
Gene (no. of patients)Mutation type and consequences
Pathogenic mutations, n = 32, 40%  
 TNFRSF6 (6) Heterozygous/LOF 
 CTLA4 (8) Heterozygous/LOF 
 STAT3 (6) Heterozygous/GOF 
 PIK3CD (1) Hetezozygous/GOF 
 CBL (1) Heterozygous/LOF 
 ADAR1 (1) Heterozygous/LOF 
 LRBA (4) Homozygous/LOF 
 RAG 1 (2) Compound heterozygous/LOF 
 TNFRSF6 somatic (1) Heterozygous/LOF 
 KRAS somatic (2) Heterozygous/GOF 
Probably pathogenic mutations, n = 20, 25%  
 Immune cell receptors  
  IFNAR1 (1) Homozygous/likely LOF 
  TNFR2 (1) Heterozygous/likely GOF 
  TGFBR2 (1) Heterozygous/likely LOF 
 Intracellular signaling  
  JAK1 (2) Heterozygous/likely GOF 
  JAK2 (1) Heterozygous/likely GOF 
  PLCG2 (1) Heterozygous/likely GOF 
  TRAF3 (1) Heterozygous/likely GOF 
  CARD11 (1) Heterozygous/likely GOF 
  ARHGEF4 (1) Heterozygous/likely GOF 
  PTPN11 (1) Heterozygous/likely GOF 
  PARP4 (1) Compound heterozygous/likely LOF 
 Apoptosis regulation  
  RIPK2 (2) Heterozygous/likely LOF 
  APAF1 (1) Heterozygous/likely GOF 
 Transcription factors  
  IKZF1 (2) Heterozygous/likely GOF 
  NFATC1 (2) Heterozygous/likely GOF 
  IKZF2 (1) Heterozygous/likely LOF 
No genetic abnormalities, n = 28, 35%  

GOF, gain of function; LOF, loss of function.

or Create an Account

Close Modal
Close Modal